Ali I. Al-Ameedi

Ali I. Al-Ameedi

Auto-generated profile, based on publicly available information

Ali I. Al-Ameedi

Veterinary Medicine Collage, Al-Qasim Green University, 51013 Babylon, Iraq

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2023 in The Iraqi Journal of Veterinary Medicine
Verified
Journal Article
Open access
PDF file
AAAli I Al-Ameedi
Ali I Al-Ameedi
FAFalah M Al-Rekabi
Falah M Al-Rekabi
In the treatment of COVID-19, the antiviral medication Favipiravir has proven to be quite successful. Its metabolism is mediated by the enzymes aldehyde oxidase (AO) and xanthine oxidase (XO). This research investigated the potential drug-drug interaction betweenfavipiravir and amlodipine in hypertensive rabbits. Twenty local adult male rabbits (aged between 10 and 12 months and weighing between 2 and 2.5 kg) were induced with hypertension by 20 mg/kg BW of desoxycorticosterone acetate subcutaneously for three weeks and then divided randomly into two groups of ten. The first group received a single oral dose of 40 mg/kg BW of favipiravir, while the second group received 5 mg/kg of amlodipine orally for 14 consecutive days to inhibit AO before receiving a single oral dose of 40 mg/kg BW of favipiravir. Blood samples were collected from the marginal ear vein at 15, 30, 45 min, and 1, 2, 4, 8, 12, 24, 48, 36, 48, and 72 h. High-performance liquid chromatography (HPLC) was used to determine the concentration of favipiravir in the plasma. The results showed that co-administration of amlodipine prolonged the time taken for favipiravir (Tmax) to reach maximum plasma concentration (Cmax) and decreased its elimination half-life, while increasing the area under the curve (AUC). Amlodipine also prolonged the elimination of favipiravir by reducing the clearance per unit time (Cl/f). Additionally, hypertension potentiated the effect of amlodipine on the absorption, distribution, metabolism, and excretion of favipiravir. In conclusion, concomitant use of favipiravir with other drugs that affect AO enzyme activity may alter the pharmacokinetic profile of the drug. Therefore, adjusting the dose of favipiravir administered to hypertensive patients receiving amlodipine is recommended.

4 July 2026 in Ukrainian Journal of Veterinary and Agricultural Sciences
Verified
Journal Article
Open access
PDF file
MSMohammed Ali Shamran
Mohammed Ali Shamran
HAHassan K. Al-Awadi
Hassan K. Al-Awadi
AAAli I. Al-Ameedi
Ali I. Al-Ameedi
Osteoporosis is a progressive skeletal disorder characterized by decreased bone mass and microarchitectural deterioration, leading to increased fracture risk. Glucocorticoid-induced osteoporosis represents a major secondary form of the disease, necessitating the exploration of safer and more effective therapeutic alternatives. Natural products rich in polyphenols, such as oak bark (Quercus pro parte), have demonstrated promising biological activities that may support bone health. This study aimed to evaluate the anti-osteoporotic effects of ethanolic extract of oak bark in methylprednisolone-induced osteoporosis in female rabbits. Fifty-six female rabbits were used, including six for acute toxicity testing (LD₅₀) and forty divided into five experimental groups: negative control, positive control (methylprednisolone-induced osteoporosis), oak bark-treated, alendronate-treated, and combination therapy (oak bark + alendronate). Osteoporosis was induced using methylprednisolone and tamoxifen. Oak bark extract (200 mg/kg/day) and alendronate (3.6 mg/kg/week) were administered for 30 days. Bone mineral density (BMD) was assessed using DEXA scanning. Serum biochemical markers, including calcium, phosphorus, vitamin D, parathyroid hormone (PTH), malondialdehyde (MDA), and superoxide dismutase (SOD), were evaluated. The phytochemical composition was analyzed by GC–MS. The LD₅₀ of oak bark extract was determined to be 1850.7 mg/kg, indicating moderate toxicity. GC–MS analysis identified bioactive compounds, including gallic acid, Linalool, and caffeic acid, with known antioxidant and anti-inflammatory properties. Osteoporotic rabbits showed significant reductions in BMD and serum calcium, phosphorus, and vitamin D levels, along with increased PTH and oxidative stress markers. Treatment with oak bark extract significantly improved these parameters (P ≤ 0.05), while combination therapy with alendronate demonstrated the most pronounced effects, restoring BMD and biochemical markers close to normal levels. Oxidative stress was markedly reduced, as evidenced by decreased MDA and increased SOD activity. Oak bark ethanolic extract exhibits significant anti-osteoporotic effects, likely mediated through its antioxidant, anti-inflammatory, and osteoprotective phytoconstituents. The combination of oak bark with alendronate showed synergistic efficacy in improving bone density and biochemical parameters. These findings suggest that oak bark may serve as a potential natural adjunct therapy for glucocorticoid-induced osteoporosis.